Metastatic Breast Cancer
The combination offered better outcomes than the THP chemo regimen.
After two years of follow-up, the new treatment improved survival and quality of life.
The new medicine offered more benefits than Faslodex.
People lived longer without the cancer growing when they received Trodelvy and Keytruda compared to the current standard treatment.
Research suggests current screening guidelines for brain mets need updating.
Some breast cancers may be more likely to come back as metastatic disease five to 10 years after surgery in people ages 35 and younger.
Treatments after surgery are more effective today and studies now include more women with lower-risk disease.
Enhertu is likely a valuable new treatment option for certain brain metastases.
Stereotactic body radiation seems best for easing pain caused by spots of metastatic cancer in the spine.
Morphine is commonly used to treat bone pain associated with metastatic breast cancer, but it also may increase bone pain and bone loss.
Tukysa plus the standard of care improved survival in people diagnosed with metastatic, HER2-positive breast cancer that had spread to the brain.
Trodelvy is now approved to treat metastatic, hormone receptor-positive breast cancer, rather than only triple-negative disease.
The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation.
The Endocrine Society has released the first guidelines on treating high calcium levels in people diagnosed with cancer.
The targeted therapy Trodelvy improved overall survival by 3.2 months in people diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that was previously treated with hormonal therapy, a CDK4/6 inhibitor, and at least two lines of chemotherapy.
People diagnosed with metastatic cancer that has spread to the bones can safely participate in supervised exercise programs, according to a review of 17 studies.
The goal is to tailor palliative care to meet each person's specific needs.
About 86% of women diagnosed with metastatic breast cancer had at least one bad treatment-related side effect, and 92% were willing to discuss options for different dosing levels of medicines based on their unique situations.
Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.
On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.
Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.
Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.
On April 17, 2020, the FDA approved Tukysa in combination with Herceptin and Xeloda to treat metastatic HER2-positive breast cancer, or locally advanced HER2-positive disease that can't be completely removed with surgery, after the cancer had been treated with at least one anti-HER2 medicine.